736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies

• Mario Sznol,
• Harriet Kluger,
• Igor Puzanov,
• Gerald S Falchook,
• Ryan Sullivan,
• Matthew H Taylor,
• Justin C Moser,
• Aaron M Ring,
• Virginia E Paton,
• David Chonzi,
• Brage Garofalo,
• Mark Sonnemann,
• Hirdesh Uppal,
• Jeremy Barton,
• Beatrice Y McQueen

Affiliations

Mario Sznol

Yale Cancer Center, Yale University, New Haven, Connecticut, USA

Harriet Kluger

2Yale Smilow Cancer Center, New Haven, CT, USA

Igor Puzanov

3Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Gerald S Falchook

2Sarah Cannon Research Institute, Denver, CO, USA

Ryan Sullivan

2Massachusetts General Hospital, Boston, MA, USA

Matthew H Taylor

Department of Internal Medicine, Seoul National University College of Medicine, Seongnam, Republic of Korea

Justin C Moser

9HonorHealth Research Instittue, Scottsdale, AZ, USA

Aaron M Ring

3Fred Hutchinson Cancer Center, Seattle, WA, USA

Virginia E Paton

7Simcha Therapeutics, Charlotte, VT, USA

David Chonzi

8Genentech Inc., South San Francisco, CA, USA

Brage Garofalo

9Simcha Therapeutics, New Haven, CT, USA

Mark Sonnemann

9Simcha Therapeutics, New Haven, CT, USA

Hirdesh Uppal

9Simcha Therapeutics, New Haven, CT, USA

Jeremy Barton

10Consultancy, New Haven, CT, USA

Beatrice Y McQueen

11Simcha Therapeutics, New Haven, CT, USA